Newsfileยท2025-11-11 19:34Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Legal Representation - Investors are advised to choose qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements achieved [5]. Group 3: Allegations Against MoonLake - The complaint alleges that during the class period, MoonLake made false or misleading statements regarding its product SLK, particularly in comparison to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6].